Welcome to our dedicated page for Ligand Pharmaceuticals news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals stock.
Ligand Pharmaceuticals Inc. (symbol: LGND) is a prominent biopharmaceutical company committed to advancing healthcare through innovative technologies and strategic partnerships. The company focuses on developing and acquiring assets that support the creation and commercialization of medicine. Ligand operates with a streamlined cost structure to maximize cash flow and enhance shareholder returns.
The company’s revenue is derived from three primary sources: royalties from commercialized products, license and milestone payments, and the sale of its proprietary Captisol material. Captisol is a chemically modified cyclodextrin that enhances the solubility and stability of drugs.
Ligand has a diverse portfolio of commercial and near-term revenue-generating assets. Its business model includes drug discovery, early-stage drug development, product reformulation, and alliances with other pharmaceutical and biotechnology companies. These partnerships and license agreements are crucial for the company’s long-term financial growth.
Recently, Ligand has made significant strides in its ongoing projects and collaborations. The company continues to build a robust pipeline with an emphasis on innovation and operational efficiency. Investors and stakeholders can expect regular updates on the company’s performance, new agreements, and advancements in drug development.
With a commitment to delivering meaningful returns and improving global health outcomes, Ligand Pharmaceuticals remains a key player in the biopharmaceutical industry. Stay informed about the latest news and developments by following Ligand's journey and updates.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its 2025 guidance during its Investor and Analyst Day, projecting total revenue of $180-200 million, representing a 17% increase over 2024. The company expects royalty revenue of $135-140 million, Captisol sales of $35-40 million, and contract revenue of $10-20 million, with core adjusted earnings per diluted share of $6.00-6.25.
The company reaffirmed its 2024 guidance of $160-165 million in total revenue and core adjusted earnings per diluted share of $5.50-5.70. Long-term projections indicate royalty receipts growing at a 22% compound annual growth rate, reaching approximately $285 million by 2029.
Over the past two years, Ligand has deployed $192 million across eight investments and is currently evaluating over $1 billion in actionable opportunities.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in the Stifel 2024 Healthcare Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will deliver a presentation on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time. The company's management team will also be available for one-on-one meetings with investors and conference attendees. Interested investors should contact their Stifel representative to schedule meetings.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced plans to host an Investor and Analyst Day in Boston on December 10, 2024, from 10:30 a.m. to 12:00 p.m. Eastern Time. The event will feature presentations from senior management covering company strategy, investment activities, royalty portfolio, and long-term financial outlook. Key features include an in-person format, a live Q&A session, and accessibility via webcast through Ligand's Investor Relations website. A replay will be available after the event.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) the same day to discuss results and provide a business update. The call will be accessible via phone and webcast, with both live and replay options available.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Travere Therapeutics received full FDA approval for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. This approval is based on positive long-term results from the PROTECT Study, showing FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Key points:
- FILSPARI is the only non-immunosuppressive treatment for IgAN
- Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI
- FILSPARI demonstrated superior long-term kidney function preservation compared to irbesartan
- The FDA-approved label includes two-year efficacy data
Ligand's CEO, Todd Davis, expressed optimism about FILSPARI's potential as a significant revenue driver for the company in the coming years.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will present on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time.
The management team is also scheduled to host one-on-one meetings with investors and attendees during the conference. Interested investors should contact their H.C. Wainwright representative to arrange these meetings.
This event provides an opportunity for Ligand to showcase its business and engage with potential investors, potentially impacting the company's stock performance and investor relations.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will report its second quarter 2024 financial results after the U.S. financial markets close on Tuesday, August 6, 2024. The company will also hold a conference call at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide a general business update. Interested parties can join the conference call using the provided phone numbers or access the live and replay webcasts online. This announcement sets the stage for investors and analysts to gain insights into Ligand's financial performance and future outlook.
Ligand Pharmaceuticals (Nasdaq: LGND) will acquire APEIRON Biologics AG for $100 million in cash, gaining royalty rights to QARZIBA®, an oncology drug for high-risk neuroblastoma marketed in 35 countries.
This acquisition will immediately increase Ligand's EPS by $1.00 annually and increase 2024 adjusted EPS guidance by 17% to $5.00-$5.50. Additional consideration up to $28 million may be paid to APEIRON based on future QARZIBA royalties by 2030 or 2034.
Ligand's 2024 revenue guidance is raised to $140 million-$157 million, and royalties expected to range from $100 million-$105 million. The transaction, approved by both companies' boards, is expected to close in July 2024.
Ligand Pharmaceuticals announced that its partner, Verona Pharma, received FDA approval for Ohtuvayre™ (ensifentrine), the first inhaled novel mechanism of action drug for COPD maintenance treatment in over 20 years. Ligand will receive a $5.8 million milestone payment and an additional $13.8 million upon commercial launch in Q3 2024. Ligand is also entitled to a low single-digit royalty on worldwide net sales of Ohtuvayre.
This marks Ligand's second FDA approval within a fortnight and the eighth since 2023. Ohtuvayre targets the multi-billion-dollar COPD market in the U.S. and is expected to bolster Ligand’s growth. The drug combines bronchodilator and non-steroidal anti-inflammatory effects, delivered via a standard jet nebulizer, enhancing ease of use for patients.
Ligand Pharmaceuticals announced that its collaborator Merck has received FDA approval for CAPVAXIVE™, a 21-valent pneumococcal conjugate vaccine for adults. This marks the sixth FDA-approved product utilizing Ligand's Pfenex Expression Technology® platform. Merck's approval triggers a $2 million milestone payment to Ligand, which is also entitled to royalties on global net sales. CAPVAXIVE, previously known as V116, is intended to prevent invasive pneumococcal disease and pneumonia. The PeliCRM197® carrier protein, enhancing antigen immunogenicity, is a key component of this vaccine. Ligand continues to collect commercial royalties on products developed with its technology, including CAPVAXIVE.